Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 8
Submit an article Journal homepage
195
Views
7
CrossRef citations to date
0
Altmetric
Theme: Breast Cancer - Drug Profile

Pertuzumab for the treatment of metastatic breast cancer

Simon P Langdon Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XU, UK. [email protected]; Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XU, UK. [email protected]
&
David A Cameron Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XU, UK; Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XU, UK
Pages 907-918 | Published online: 10 Jan 2014

References

  • Cardoso F, Bischoff J, Brain E et al. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat. Rev. 39(5), 457–465 (2013).
  • Cardoso F, Senkus-Konefka E, Fallowfield L et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), 15–19 (2010).
  • Nielsen DL, Kumler I, Palshof JAE et al. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 22(1), 1–12 (2013).
  • Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
  • Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127–137 (2001).
  • Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signalling and therapeutics. Curr. Opin. Cell Biol. 19, 124–134. (2007).
  • Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341–354 (2005).
  • Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756–760 (2003).
  • Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res. Treat 131, 371–383 (2012).
  • Arteaga CL, Sliwkowski MX, Osborne CK et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9, 16–32 (2011).
  • Adams CA, Allison DE, Flagella K et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol. Immunother. 55, 717–727 (2006).
  • Franklin MC, Carey KD, Vajdos F et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5, 317–328 (2004).
  • Badache A, Hynes NE. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 5, 299–301 (2004).
  • Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
  • Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  • Toi M, Iwata H, Fujiwara Y et al. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients Phase II studies. Br. J. Cancer 101, 1676–1682, (2009).
  • Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26, 2999–3005 (2008).
  • Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733–2743 (2006).
  • Guan Z, Xu B, Arpornwirat W et al. Overall survival benefit observed with lapatinib (L) plus paclitaxel (P) as first line therapy in patients with HER2-overexpressing metastatic breast cancer (MBC). Cancer Res. 70(Suppl.), SABCS10-P3-14-24 (2010).
  • Gelmon KA, Boyle F, Kaufman B et al. Open-label Phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J. Clin. Oncol. 30(Suppl.), LBA671 (2012).
  • Barginear MF, John V, Budman DR. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol. Med. 18, 1473–1479 (2013).
  • Burris HA 3rd, Rugo HS, Vukelja SJ et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)- positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29, 398–405 (2011).
  • Krop IE, Lorusso P, Miller KD et al. A Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2 -positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30, 3234–3241 (2012).
  • Hurvitz SA, Dirix L, Kocsis J et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 31, 1157–1163 (2013).
  • Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
  • Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28, 1301–1307 (2010).
  • Saura C, Garcia-Saenz JA, Xu B et al. Safety and efficacy of neratinib in combination with capecitabine in patients with ErbB2-positive breast cancer. Cancer Res. 71(24 Suppl.), abstract P1-12-09 (2011).
  • Lin NU, Winer EP, Wheatley D et al. A Phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res. Treat 133, 1057–1065 (2012).
  • Moulder SL, Baetz T, D’Aloisio S et al. A Phase 1 study to assess the safety, tolerability and PK of ARRY-380-an oral HER2 inhibitor. Cancer Res. 70s, abstract 262 (2010).
  • Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2, 127–137 (2002).
  • Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64, 2343–2346 (2004).
  • Scheuer W, Friess T, Burtscher H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 69, 9330–9336 (2009).
  • Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 23, 2534–2543 (2005).
  • Yamamoto N, Yamada Y, Fujiwara Y et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in japanese patients with solid tumors. Jpn. J. Clin. Oncol. 39, 260–266 (2009).
  • Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 24, 4324–4332 (2006).
  • Gianni L, Lladó A, Bianchi G et al. Open-label, Phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 1131–1137 (2010).
  • Walshe JM, Denduluri N, Berman AW et al. A Phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin. Breast Cancer 6, 535–539 (2006).
  • Attard G, Kitzen J, Blagden SP et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br. J. Cancer 97, 1338–1343 (2007).
  • Albanell J, Montagut C, Jones ET et al. A Phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin. Cancer Res. 14, 2726–2731 (2008).
  • de Bono JS, Bellmunt J, Attard G et al. Open-label Phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J. Clin. Oncol. 25, 257–262 (2007).
  • Herbst RS, Davies AM, Natale RB et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin. Cancer Res. 13, 6175–6181 (2007).
  • Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138–1144 (2010).
  • Portera CC, Walshe JM, Rosing DR et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin. Cancer Res. 14, 710–716 (2008).
  • Cortes J, Fumoleau P, Bianchi GV et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30, 1594–1600 (2012).
  • Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109–119 (2012).
  • Swain SM, Kim S-B, Cortes J et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Res. 72(24 Suppl.), Abstract nr P5-18-26 (2012).
  • Bachelot T, Ciruelos E, Peretz-Yablonski T et al. A single-arm Phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE). Cancer Res. 72(24 Suppl.), Abstract nr 12-OT1-1-02 (2012).
  • Munoz-Mateu M, Urruticoechea A, Separovic R et al. Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, Phase II study (PHEREXA). J. Clin. Oncol. 29(Suppl.), Abstract TPS118 (2011).
  • Perez EA, Lopez-Vega JM, Mastro LD et al. A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: an open-label, two-cohort, Phase II study (VELVET). J. Clin. Oncol. 30(Suppl.) Abstract TPS653 (2012).
  • Rimawi MF, Poole CJ, Ferrero J-M et al. Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: a randomized Phase II study (PERTAIN). J. Clin. Oncol. 30(Suppl.), Abstract TPS654 (2012).
  • Datko F, D’Andrea G, Dickler M et al. A Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC). Cancer Res. 72(24 Suppl.), Abstract nr P5-18-20 (2012).
  • Lewis Phillips GD, Fields CT, Crocker L et al. Potent anti-tumor activity of trastuzumab-DM1 antibody-drug conjugate in combination with cytotoxic chemotherapeutic agents, antibodies or small molecule kinase inhibitors. Proc. AACR Abstract 2133 (2008).
  • Fields CT, Crocker LM, Sliwkowski MX et al. Dual targeting of HER2: Enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab. Proc AACR Abstract 5607 (2010).
  • Diéras V, Harbeck N, Albain K et al. A Phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Cancer Res. 70(24 Suppl.), Abstract nr P3-14-01 (2010).
  • LoRusso P, Weiss D, Guardino E et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 17, 6437–6477 (2011).
  • Modi S, Elias AD, LoRusso P et al. Results from a Phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. J. Clin. Oncol. 30(Suppl.), Abstract 528 (2012).
  • Martin M, Garcia-Saenz JA, Dewar JA et al. Interim results from a Phase 1b/2a study of trastuzumab emtansine and docetaxel, with and without pertuzumab, in patients with HER2-positive locally advanced or metastatic breast cancer. Cancer Res. 72(24 Suppl.), Abstract nr P5-18-05 (2012).
  • Ellis PA, Barrios CH, Im Y et al. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). J. Clin. Oncol. 29(Suppl.), Abstract TPS102 (2011).
  • Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25–32 (2012).
  • Minckwitz GV, Baselga J, Bradbury I et al. Adjuvant pertuzumab and herceptin in initial therapy of breast cancer: APHINITY (BIG 4–11/BO25126/TOC4939g). Cancer Res. 71(24 Suppl.), Abstract nr OT1-02-04 (2011).
  • Lenihan D, Suter T, Brammer M et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann. Oncol. 23, 791–800 (2012).
  • Drucker AM, Wu S, Dang CT et al. Risk of rash with the anti-HER2 dimerization antibodypertuzumab: a meta-analysis. Breast Cancer Res. Treat. 135, 347–354 (2012).
  • Olson EM. Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy. J. Clin. Oncol. 30, 1712–1714 (2012).
  • Constantinidou A, Smith I. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Breast 20(Suppl. 3), S158–S161 (2011).
  • Nahta R. Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol. 2012, 428062 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.